GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Alembic Pharmaceuticals Ltd

Alembic Pharma Q2 FY27 Consolidated Revenue Up 36% to Rs. 2,603.48 Crores

RESULTS ▲ Positive Development LOW RISK
📅 Filed on BSE: 04 Nov 2026, 02:26 PM IST  ·  BSE ID: a498fc7f-5354-4df9-9452-cfd62585f167
View Original BSE Filing (PDF)
💡
In Simple Terms
Alembic Pharma's latest quarterly sales went up significantly, and its profit more than doubled compared to last year.
🤖 AI Summary
  • Alembic Pharmaceuticals reported consolidated revenue from operations at Rs. 2,603.48 Crores for Q2 FY27.
  • Profit for the period after non-controlling interests increased to Rs. 335.17 Crores for Q2 FY27.
  • Diluted Earnings per Share (EPS) stood at Rs. 17.05 for the quarter ended September 30, 2026.
  • Total comprehensive income for the period reached Rs. 328.86 Crores.
  • The Board of Directors approved the unaudited consolidated and standalone financial results on November 4, 2026.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Revenue from Operations (Q2 FY27)
Rs. 2,603.48 Crores
36.20%
Profit for the Period after non-controlling interests (Q2 FY27)
Rs. 335.17 Crores
81.46%
Earnings per share – Basic & Diluted (Q2 FY27)
Rs. 17.05
81.38%
Revenue from Operations (Half Year FY27)
Rs. 4,753.25 Crores
31.26%
Profit for the Period after non-controlling interests (Half Year FY27)
Rs. 508.23 Crores
49.88%
🏢 How This Affects the Company
📈
Business Impact
Consolidated revenue from operations increased by 36.20% YoY, indicating growth in market penetration or sales volumes. The company continues to generate significant sales from its pharmaceuticals business.
💰
Financial Impact
Profit for the period after non-controlling interests rose 81.46% YoY to Rs. 335.17 Crores. Operating Margin improved to 22.21% in Q2 FY27 from 17.02% in Q2 FY26, suggesting enhanced profitability. Net Profit Margin also increased to 12.87% from 9.67% YoY.
👥 What This Means For Shareholders
✅
Action Required
No action required by shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected by the company's financial performance, with Q2 FY27 diluted EPS at Rs. 17.05 compared to Rs. 9.40 in Q2 FY26.
🔍
Management Signal
The approval and disclosure of robust consolidated unaudited financial results signals management's focus on operational performance and profitability.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Q3 FY27 financial results for continued revenue and profit growth trend.
Updates on segment-wise performance in subsequent filings.
Any further disclosures regarding other comprehensive income movements.
LOW RISK The filing reports strong financial results with no new risks identified within the document.
💡 Investor Takeaway
Alembic Pharmaceuticals reported Q2 FY27 consolidated revenue from operations of Rs. 2,603.48 Crores, a 36.20% increase from Q2 FY26. Profit after non-controlling interests for the period was Rs. 335.17 Crores, up 81.46% YoY. Diluted EPS for Q2 FY27 stood at Rs. 17.05.
⚖️ Strengths & Concerns

✅ Positives

  • Consolidated Revenue from Operations grew 36.20% year-on-year to Rs. 2,603.48 Crores in Q2 FY27 from Rs. 1,910.15 Crores in Q2 FY26.
  • Profit for the period after non-controlling interests increased 81.46% year-on-year to Rs. 335.17 Crores in Q2 FY27 from Rs. 184.71 Crores in Q2 FY26.

⚠️ Concerns

  • Share of Profit/(Loss) of Associates and Joint Ventures showed a loss of Rs. (1.37) Crores in Q2 FY27, compared to a profit of Rs. 1.42 Crores in Q2 FY26.
  • Other Comprehensive Income showed a total loss of Rs. (5.05) Crores for Q2 FY27, compared to a gain of Rs. 4.67 Crores in Q2 FY26.
📅 Company Track Record
Alembic Pharmaceuticals reported Q1 FY27 consolidated revenue of Rs. 2,149.77 Crores, with profit at Rs. 173.07 Crores. This followed a previous filing indicating Q1 FY27 revenue up 26% and PAT up 12% YoY, establishing a trend of revenue and profit growth in FY27.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Alembic Pharmaceuticals' consolidated revenue in Q2 FY27?
Alembic Pharmaceuticals reported consolidated revenue from operations of Rs. 2,603.48 Crores for the quarter ended September 30, 2026 (Q2 FY27).
What was Alembic Pharmaceuticals' net profit in Q2 FY27?
Profit for the period after non-controlling interests for Alembic Pharmaceuticals was Rs. 335.17 Crores in Q2 FY27, compared to Rs. 184.71 Crores in Q2 FY26.
What was Alembic Pharmaceuticals' Earnings per Share (EPS) for Q2 FY27?
Alembic Pharmaceuticals' Basic & Diluted Earnings per Share was Rs. 17.05 for the quarter ended September 30, 2026 (Q2 FY27).
How did Alembic Pharmaceuticals' half-year revenue perform in FY27?
For the half year ended September 30, 2026, Alembic Pharmaceuticals' consolidated revenue from operations was Rs. 4,753.25 Crores, up from Rs. 3,620.87 Crores in the prior half-year.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again — explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.